| Complication | Evidence | PMID |
| Nephropathy | 1. Elevated serum FGF21 levels may be a useful biomarker for predicting kidney disease progression especially in early stages of diabetic nephropathy. 2. Our suggest that FGF21 improves insulin resistance and protects against renal injury through both improvement of systemic metabolic alterations and antifibrotic effects in type 2 diabetic nephropathy. | 25625802 |
| Cardiovascular | 1. Higher baseline plasma FGF21 levels were associated with higher risk of cardiovascular events in patients with type 2 diabetes. | 25425220 |
| Retinopathy | 1. Higher baseline FGF21 levels are seen in patients with type 2 diabetes and established microvascular disease, and predict the future development of new microvascular disease. | 26055067 |
| Atherosclerosis | 1. In humans, circulating FGF21 levels are elevated in corory heart disease and atherosclerosis, and are associated with a higher risk of cardiovascular events in patients with type 2 diabetes. | 26379627 |
| Dyslipidemia | 1. In logistic regression analysis, circulating FGF21 was found to be an independent predictor for subclinical atherosclerosis (P?=?0.023) in addition to dyslipidemia, hypertension and adiponectin. | 26379627 |
| Insulin resistance and inflammation | 1. these results indicate that circulating levels of FGF21 are increased in patients presenting with sepsis and SIRS, and suggest a role for FGF21 in inflammation. | 30641825 |
